Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m(2) and Once-Weekly at 70 mg/m(2) in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

Autor: Leleu, X, Beksac, M, Chou, T, Dimopoulos, M, Yoon, SS, Prince, HM, Pour, L, Shelekhova, T, Chari, A, Khurana, M, Obreja, M, Qi, M, Oriol, A, Siegel, D
Rok vydání: 2020
Předmět:
Zdroj: Clinical Lymphoma Myeloma & Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
ISSN: 2152-2650
Databáze: OpenAIRE